Treatment for hemophilia A consists of injecting the missing factor VIII I.V. to prevent or stop bleeding. A majority of the complications of this treatment are the development of antibodies against FVIII, called inhibitors.
The development of an anti-FVIII inhibitor leads to episodes of bleeding that are difficult to control.
The activity of the inhibitor is measured by the Bethesda assays or modified  Nijmegen Bethesda and is expressed in BU. 1BU neutralizes 50% of the activity of FVIII for hemophilia A.

Control titrated to the cut-off value according to HAS recommendations.

- The stability of the product is 7 days at -20 °C
- Bethesda Unit title depending on lots and tests (close to 1.5 Bethesda Unit)

- 25 cryotubes x 0.5 mL of frozen plasma

CRYOcheck™ Factor VIII Inhibitor Kit
Factor IX Inhibitor Plasma Negative Control
Factor IX Inhibitor Plasma Weak Control
Factor VIII Inhibitor Plasma
Factor VIII Inhibitor Plasma HCV neg
Factor VIII Inhibitor Plasma Negative Control